Tolvaptan

From Citizendium
Revision as of 09:20, 17 October 2010 by imported>Gareth Leng
Jump to navigation Jump to search
This article is a stub and thus not approved.
Main Article
Discussion
Definition [?]
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Uses

Tolvaptan can be used for euvolemic or hypervolemic hyponatremia.[1][2][3] However, vasopressin receptor antagonist may increase the frequency of rapid sodium correction although osmotic demyelination syndrome may not be increased.[1]

Tolvaptan can be used for heart failure.[4][5]

References

  1. 1.0 1.1 Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U (2010). "Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis.". Am J Kidney Dis 56 (2): 325-37. DOI:10.1053/j.ajkd.2010.01.013. PMID 20538391. Research Blogging.
  2. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS et al. (2006). "Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.". N Engl J Med 355 (20): 2099-112. DOI:10.1056/NEJMoa065181. PMID 17105757. Research Blogging.
  3. (2009) Tolvaptan (Samsca) for Hyponatremia The Medical Letter
  4. Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K et al. (2007). "Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.". JAMA 297 (12): 1332-43. DOI:10.1001/jama.297.12.1332. PMID 17384438. Research Blogging.
  5. Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K et al. (2007). "Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.". JAMA 297 (12): 1319-31. DOI:10.1001/jama.297.12.1319. PMID 17384437. Research Blogging.